Sedation Clinical Trial
Official title:
Pharmacokinetics and Pharmacodynamics of Three Doses of Oral Trans-mucosal Dexmedetomidine for Premedication in Patients Undergoing Modified Radical Mastectomy
Oral trans-mucosal administration is relatively easy and convenient, it also reduces first pass metabolism and has been used successfully for fentanyl, ketamine, and midazolam premedication.
The alpha2-adrenoceptor agonist, dexmedetomidine, was originally developed as a sedative and
analgesic drug for use in intensive care. However, it has a number of unique pharmacodynamic
properties, which also make it useful in anesthesia including; decreased MAC, analgesia
without respiratory depression and a significant reduction in catecholamine secretion. Also
it has been used off-label as an adjunctive agent for sedation and analgesia in patients in
the critical care unit and for sedation during non-invasive procedures in radiology. It also
has a potential role as part of anesthesia care to prevent emergence delirium and
post-anesthesia shivering.
Oral trans-mucosal administration is relatively easy and convenient, it also reduces first
pass metabolism and has been used successfully for fentanyl, ketamine, and midazolam
premedication.
The current literature is focused in studying the sedative and analgesic effects of
intravenously administered dexmedetomidine. Pharmacodynamics and pharmacokinetic studies
undertaken on alternative routes of dexmedetomidine administration are lacking. The
pharmacokinetic properties of trans-mucosal administration of dexmedetomidine have been
demonstrated in one study only, and the clinical effects of non-parenteral administration of
dexmedetomidine have been described in anecdotal case reports.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT03399019 -
Bispectral Index(BIS) on Depth of Sedation With Dexmedetomidine, Propofol and Midazolam During Spinal Anesthesia
|
N/A | |
| Completed |
NCT03220880 -
Intranasal Dexmedetomidine Sedation in Children for Non-painful Procedures
|
||
| Recruiting |
NCT04820205 -
Comparison of Oral Chloral Hydrate and Combination of Intranasal Dexmedetomidine and Ketamine for Procedural Sedation in Children
|
N/A | |
| Recruiting |
NCT04549623 -
End-Tidal Carbon Dioxide Monitoring Device for Sedation During Endoscopic Ultrasonography
|
N/A | |
| Recruiting |
NCT04822064 -
Comparison of Oral Chloral Hydrate and Combination of Intranasal Dexmedetomidine and Ketamine for Rescue After Failed Pediatric Procedural Sedation
|
N/A | |
| Completed |
NCT01001533 -
Assess the Ability of Electrical Cardiometry to Trend Hemodynamic Variables During Dexmedetomidine Sedation
|
N/A | |
| Completed |
NCT01527903 -
A Comparison Between Propofol-Remifentanil and Midazolam-Remifentanil Sedation in the Intensive Care Unit
|
Phase 4 | |
| Completed |
NCT00747721 -
Pharmacokinetics of Dexmedetomidine During Prolonged Infusion in ICU
|
Phase 1 | |
| Completed |
NCT00158873 -
Pharmaco-Economic Study Of Ultiva In Intensive Care Unit(ICU)Subjects
|
Phase 4 | |
| Terminated |
NCT00205517 -
Sedation and Psychopharmacology in Critical Care
|
N/A | |
| Recruiting |
NCT04096768 -
The Use of Ketamine and Dexmedetomidine in Intensive Care Sedation
|
Phase 3 | |
| Active, not recruiting |
NCT05082623 -
The Effect of Music on Delirium, Pain, Need of Sedation, Anxiety and Vital Parameters
|
N/A | |
| Suspended |
NCT03285165 -
Cerebral Vascular Effects of Dexmedetomidine Versus Propofol Sedation in Intubated Mechanically Ventilated ICU Patients
|
Phase 2/Phase 3 | |
| Active, not recruiting |
NCT04788589 -
Sedation and Ventilator Weaning Protocol in PICU
|
N/A | |
| Completed |
NCT03425474 -
Study of Remimazolam Tosilate in Patients Undergoing Diagnostic Upper GI Endoscopy
|
Phase 3 | |
| Recruiting |
NCT06061159 -
The ED95 of Single Intravenous Bolus Remimazolam Besylate in Pediatric Patients During General Anesthesia Induction
|
Phase 4 | |
| Completed |
NCT06449365 -
Comparison of Intravenous V/S Nasal Atomizer Delivery of Midazolam for Conscious Sedation for No-scalpel Vasectomy
|
Phase 4 | |
| Completed |
NCT02171910 -
Doxapram as an Additive to Propofol Sedation in Sedation for ERCP
|
Phase 4 | |
| Completed |
NCT02211118 -
Sedation and Physiological Effects of Intranasal Dexmedetomidine in Severe COPD
|
Phase 4 | |
| Completed |
NCT01694745 -
EUROpean Pain Audit In Neonates
|
N/A |